Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
1.35 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Anticancer Fund (ACF)
EU Transparency Register
404359320127-95 First registered on 30 Dec 2015
Goals / Remit
The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.
The Anticancer Fund is a foundation of public utility with an international reach that focuses on the cure of cancer patients by:
- Supporting the development of promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
- Providing free comprehensive, evidence-based information about cancer treatments.Main EU files targeted
Europe’s Beating Cancer Plan
Horizon: EU4Health and Missions
New Pharmaceutical Strategy
MAC Group (Members of Parliament Against Cancer)
Cancer related policies
Research and clinical trials
Market authorisation for innovative medicines
Revision of the Pharmaceutical LegislationAddress
Head Office
Brusselsesteenweg 11
Meise 1860
BELGIUMEU Office
Brusselsesteenweg 11
Meise 1860
BELGIUMWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 100% 1 25% 1 10% 1 Lobbyists (Full time equivalent)
1.35
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
https://www.icrpartnership.org/
https://www.europeancancer.org/
https://bigagainstbreastcancer.org/collaborations/patient-advocates/ (BIG: Patient Partnership Initiative)
https://www.ovacure.org/en/ (Scientific Board)
https://c-path.org/programs/cdrc/ (Cure Drug Repurposing Collaboratory)
https://consilium-scientific.org/ (Advisory Board)Member organisations
None declared
-
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
979,777€
Major funding types in closed year
Other, EU funding, Donations
Funding types "other" information
Major contributions in closed year
Type Name Amount Contribution Baltisse NV 250,000€ Contribution EATRIS for REMEDI4ALL 149,603€ Contribution Belfius 100,000€ Grant EATRIS 149,603€ Major contributions in current year
Type Name Amount Grant EATRIS 91,654€ Other financial info
The grant from EATRIS (REMEDI4ALL) for the amount of 91654 euro refers to the year 2024
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
Cancer
Communication activities
1. Member of the Repurposing Observatory Group (RepOG)
2. Remedi4All was launched in September 2022: an ambitious EU-funded research initiative to drive forward the repurposing of medicines in Europe. The ACF is one of the consortium partners and has taken the lead in the organisation of the cancer path at the first international drug repurposing conference (#iDR24) that took place on 6 and 7 March 2024.
3. Targeted EU Contact Program on cancer related policy: Webinar to raise awareness among policymakers, researchers, physicians and patients of the potential of repurposed drugs in the treatment of cancer against the backdrop of the COVID-19 pandemic.
4. Stakeholder Contact Group EBCP
5. Since 2017, the ACF was invited for STAMP meetings on the topic of drug repurposing. The ACF actively contributed to drafting the framework proposal for drug repurposing.
6. BE Presidency invitation to joint meeting NCAPR/HTA-HAG/HMA related to Drug Repurposing Keynote Speach
7. Since 2019, the ACF has been providing feedback to the commission through surveys and public consultations on Europe’s beating cancer plan, the cancer mission, the pharmaceutical strategy, Revision of EU rules on medicines for children and rare diseases and on the revision of the pharmaceutical legislation.
On 21 may 2021, ACF was invited to participate in the Pharmaceutical Committee on the subject of: “Future proofing of the legislation and incentives for innovation that reaches the patient”.
8. The ACF formulates its recommendations to the Mission Board and has F-2-F meetings with different MEPs.Other activities
None declared
Meetings
Meetings
None declared